• Explore /
  • Poster
  • / An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.

Abstract Poster

Authors

null

Arvind Dasari

The University of Texas MD Anderson Cancer Center, Houston, TX

Arvind Dasari , John S. Kauh , Christopher Tucci , Shivani Nanda , Marek K. Kania , Jennifer W Carlisle , Andrew Scott Paulson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT04579757

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2677)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2677

Abstract #

TPS2677

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Gerald Steven Falchook

Poster

2022 ASCO Annual Meeting

Surufatinib in U.S. patients with soft tissue sarcoma.

Surufatinib in U.S. patients with soft tissue sarcoma.

First Author: Sujana Movva

First Author: Thorsten Oliver Goetze